Albendazole therapy for neurocysticercosis [2] (multiple letters)

Neurology

Volumn 50, Issue 3, 1998, Pages 834-835

  Ko, D Y ^a   Chang, G Y N ^a   Takayanagui, O M ^a   Garcia, H H ^a   Martinez, S M ^a   Herrera, G ^a   Gilman, R H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; DEXAMETHASONE; METHYLPREDNISOLONE; PRAZIQUANTEL; PREDNISOLONE; ANTHELMINTIC AGENT;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG EFFICACY; HEALTH CARE COST; HUMAN; HUMAN TISSUE; LETTER; META ANALYSIS; MEXICO; MINIMUM INHIBITORY CONCENTRATION; NEUROCYSTICERCOSIS; PRIORITY JOURNAL; BRAIN DISEASE; CYSTICERCOSIS; NOTE;

ALBENDAZOLE; ANTHELMINTICS; BRAIN DISEASES; CYSTICERCOSIS; HUMANS;

EID: 0031920706     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.50.3.834-b     Document Type: Letter

References (18)